gynecology and obstetrics medical project, gynecology journal, obstetrics, gynecologic oncology, reproductive medicine, gynecological endoscopy, ultrasonography, gynecology articles

Ginekologia i Poloznictwo
ISSN 1896-3315 e-ISSN 1898-0759

Prevalence of the polycystic ovary syndrom in adolescents treated with GnRH analogues due to precocious puberty



Polycystic ovary syndrome is one of the most frequent hormonal disorders in women (it affects about 4-12% women). Etiology of polycystic ovary syndrome is not clear. Nowadays many scientists consider treatment with GnRH analogues in childhood (due to central precocious puberty) as a risk factor of PCOS. There is no consensus in current publications: in some of them GnRH treatment is an independent risk factor of polycystic ovary syndrome), in others researchers do not find the correlation between GnRH treatment and polycystic ovary syndrome. There is no agreement about the diagnostic criteria of polycystic ovary syndrome in adolescence either. The Rotterdam criteria, National Institutes of Health and Androgen  Society criteria were used. It seems justifiable to use the criteria proposed by the members of Amsterdam ESHRE/ASRM-Sponsored 3rd PCOS Consensus Workshop, which take into account the physiology of an adolescent woman. There is a necessity of more researches which will include three groups of young women: women diagnosed with central precocious puberty treated with GnRH analogues, women with central precocious puberty untreated and healthy women.